ProCyto Labs has successfully licensed its novel ophthalmic formulation to Farmigea, a renowned 75-year-old Italian ophthalmic pharmaceutical company. The agreement was concluded ahead of both patent grant and clinical trials, marking a significant milestone in ProCyto Labs’ translational innovation journey. As a part of this agreement, has undertaken the European patent coverage and secured rights for the further development and commercialization of the formulation within the European territory. The licensing reflects the strong scientific foundation, translational potential, and global relevance of the technology. The recognition of our innovation by an internationally established ophthalmic pharmaceutical company is both a proud validation and a deeply encouraging moment for our team. It reinforces our commitment to advancing impactful healthcare solutions through science-driven research and innovation.
Novel Eye Formulation Successfully Licensed to Farmigea, Italy
